북미의 디지털 병리학 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 제품별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

North America Digital Pathology Market Growth & Trends:

The North America digital pathology market size is expected to reach USD 693.9 million in 2030 and is expected to grow at a CAGR of 7.8% from 2025 to 2030. The market is predominantly driven by the growing prevalence of chronic diseases such as cancer. As a consequence of the high prevalence of cancer, pathologists require data that facilitate personalizing therapy for patients. Hence, digital pathology is progressively being selected by pathologists as it has various benefits including accelerated diagnosis rate, diagnostic accuracy, and offers therapeutic recommendations to improve patient outcomes.

The growing number of collaborative agreements to develop as well as expedite the adoption of digital pathology in cancer diagnostics serves as a key growth factor contributing to the market. The use of artificial intelligence in digital pathology has gained momentum in the past years. The increasing need for lowering healthcare costs, increasing importance of big data in healthcare, rising adoption of precision medicine, and declining hardware costs are some factors driving the growth. In addition, increasing usage of artificial intelligence-based analytical tools in healthcare and high capital investments in this field are further propelling the market growth.

During the coronavirus outbreak, the exponential need for home-based workstations and safe clinical informatics systems allowing healthcare professionals to read images remotely and enabling virtual collaboration between their multi-disciplinary care teams has increased. Various histopathology departments in the region faced a reducing workforce and increasing workload during the pandemic. Digital pathology considered being the potential solution for some of the challenges faced by the pathologist, there is an increase in the adoption of digital diagnosis of disease during coronavirus outbreak.

In April 2020, Philips announced that the FDA granted a waiver for home use of consumer monitors with the company's IntelliSite Pathology Solution during the emergency. The temporary exemption of restrictions on remote use of the digital pathology helps pathologists to access whole slide images from home and fasten the diagnosis of histology cases. Some pathology labs that have adopted DP in their workflows across different sites pre-COVID-19, reported improved collaboration, and an average productivity gain of 21.0% with operation efficiency increased by 13.0%. These types of initiatives are anticipated to fuel market growth.

North America Digital Pathology Market Report Highlights:

• North America digital pathology market is currently experiencing significant growth, at an accelerating pace
• The device segment held the largest share of 52.07% in 2024
• The human pathology segment held the largest share in 2024
• The academic research segment dominated the market in 2024he forecast period
• The digital pathology market in the U.S. dominated the regional market with the largest share in 2024

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database:
  • 1.3.2. Gvr's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research:
  • 1.3.5. Details Of Primary Research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for Primary Interviews in Europe
    • 1.3.5.3. Data for Primary Interviews in APAC
    • 1.3.5.4. Data for Primary Interviews in Latin America
    • 1.3.5.5. Data for Primary Interviews in MEA
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Top Down Market Estimation
  • 1.6.3. CAGR Calculation
  • 1.6.4. Key Report Updates
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Report Objectives
  • 1.9.1. Objective - 1
  • 1.9.2. Objective - 2

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segmental Snapshot
• 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Analysis
  • 3.1.2. Ancillary Market Analysis
• 3.2. North America Digital Pathology Market- Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Higher cost-efficiency
    • 3.2.1.3. Rapid technological advancements in the overall digital pathology market
      • 3.2.1.3.1. Competitive Factors and Strategies
      • 3.2.1.3.2. List of Top Notable Funded Digital Pathology Companies
      • 3.2.1.3.3. Top 10 Vendor - by Total Funding from 2014 - 2021 (Potential vendors for collabrations)
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of skilled professionals
    • 3.2.2.2. High cost of implementing digital pathology solutions
  • 3.2.3. Market Challenges Analysis
• 3.3. North America Digital Pathology Market Analysis Tools: Porters Five Forces
  • 3.3.1. Bargaining power of the suppliers
  • 3.3.2. Bargaining power of the buyers
  • 3.3.3. Threats of substitution
  • 3.3.4. Threats from new entrants
  • 3.3.5. Competitive rivalry
• 3.4. PESTLE Analysis
  • 3.4.1. Political landscape
  • 3.4.2. Economic and Social landscape
  • 3.4.3. Technological landscape
  • 3.4.4. Environmental landscape
  • 3.4.5. Legal landscape
• 3.5. Case Studies & Inisghts
• 3.6. Impact of COVID 19

Chapter 4. North America Digital Pathology Market: Product Estimates & Trend Analysis

• 4.1. North America Digital Pathology Market, Product Type: Key Takeaways
• 4.2. North America Digital Pathology Market: Product Type Movement & Market Share Analysis, 2024 & 2030
• 4.3. Software
  • 4.3.1. Software Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
• 4.4. Devices
  • 4.4.1. Devices Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.4.2. Scanners
    • 4.4.2.1. Scanners market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.4.3. Slide Management System
    • 4.4.3.1. Slide management system market estimates and forecast, 2018 - 2030 (USD Million)
• 4.5. Storage Systems
  • 4.5.1. Storage Systems Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. North America Digital Pathology Market: Type Estimates & Trend Analysis

• 5.1. North America Digital Pathology Market, by Type: Key Takeaways
• 5.2. North America Digital Pathology Market: Type Movement & Market Share Analysis, 2024 & 2030
• 5.3. Veterinary Pathology
  • 5.3.1. Veterinary Pathology Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
• 5.4. Human Pathology
  • 5.4.1. Human Pathology Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. North America Digital Pathology Market: Application Estimates & Trend Analysis

• 6.1. North America Digital Pathology Market, Application Type: Key Takeaways
• 6.2. North America Digital Pathology Market: Application Movement & Market Share Analysis, 2024 & 2030
• 6.3. Drug Discovery & Development
  • 6.3.1. Drug Discovery & Development Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
• 6.4. Academic Research
  • 6.4.1. Academic Research Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
• 6.5. Disease Diagnosis
  • 6.5.1. Disease Diagnosis Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.5.2. Cancer Cell Detection
    • 6.5.2.1. Cancer Cell Detection Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.5.3. Others
    • 6.5.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. North America Digital Pathology Market: End Use Estimates & Trend Analysis

• 7.1. North America Digital Pathology Market, By End Use: Key Takeaways
• 7.2. North America Digital Pathology Market: End Use Movement & Market Share Analysis, 2024 & 2030
• 7.3. Hospitals
  • 7.3.1. Hospitals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.4. Biotech & Pharma Companies
  • 7.4.1. Biotech & Pharma Companies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Diagnostics Labs
  • 7.5.1. Diagnostics Labs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6. Academic & Research Institutes
  • 7.6.1. Academic & Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. North America Digital Pathology Market: Country Estimates & Trend Analysis

• 8.1 North America Digital Pathology Market: Regional Movement Analysis, 2024 & 2030
• 8.2 Regional Market Dashboard
• 8.3 Regional Market Snapshot
  • 8.3.1 North America
    • 8.3.1.1 North America Digital Pathology Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.3.1.2 U.S.
      • 8.3.1.2.1 Key Country Dynamics
      • 8.3.1.2.2 Competitive Scenario
      • 8.3.1.2.3 Regulatory Framework
      • 8.3.1.2.4 Reimbursement Scenario
      • 8.3.1.2.5 U.S. Digital Pathology Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.3.1.3 Canada
      • 8.3.1.3.1 Key Country Dynamics
      • 8.3.1.3.2 Competitive Scenario
      • 8.3.1.3.3 Regulatory Framework
      • 8.3.1.3.4 Reimbursement Scenario
      • 8.3.1.3.5 Canada Digital Pathology Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.3.1.4 Mexico
      • 8.3.1.4.1 Key Country Dynamics
      • 8.3.1.4.2 Competitive Scenario
      • 8.3.1.4.3 Regulatory Framework
      • 8.3.1.4.4 Reimbursement Scenario
      • 8.3.1.4.5 Mexico Digital Pathology Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Competitive Market Entry Strategies
• 9.3. Private Companies/ Vendors, By Country/Region
• 9.4. Company Market Share/Position Analysis, 2024
• 9.5. Company Profiles/Listing
  • 9.5.1. Leica Biosystems Nussloch GmbH (Danaher)
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Hamamatsu Photonics, Inc
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Koninklijke Philips N.V.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Olympus Corporation
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. F. Hoffmann-La Roche Ltd
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Mikroscan Technologies, Inc
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Inspirata, Inc.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Epredia (3DHISTECH Ltd.)
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Huron Technologies International Inc.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. CellaVision
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Morphle Labs, Inc
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. Bionovation Biotech, Inc
    • 9.5.12.1. Overview
    • 9.5.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Strategic Initiatives